Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown.
Shortly after the cellular mechanism of RNA interference (RNAi) was first described, scientists began using this powerful technique to study gene function. This included designing better methods for the successful delivery of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) into mammalian cells. While the simplest method for RNAi is the cytosolic delivery of siRNA oligonucleotides, this technique is limited to cells capable of transfection and is primarily utilized during transient in vitro studies. The introduction of shRNA into mammalian cells through infection with viral vectors allows for stable integration of shRNA and long-term knockdown of the targeted gene; however, several challenges exist with the implementation of this technology. Here we describe some well-tested protocols which should increase the chances of successful design, delivery, and assessment of gene knockdown by shRNA. We provide suggestions for designing shRNA targets and controls, a protocol for sequencing through the secondary structure of the shRNA hairpin structure, and protocols for packaging and delivery of shRNA lentiviral particles. Using real-time PCR and functional assays we demonstrate the successful knockdown of ASC, an inflammatory adaptor molecule. These studies demonstrate the practicality of including two shRNAs with different efficacies of knockdown to provide an additional level of control and to verify dose dependency of functional effects. Along with the methods described here, as new techniques and algorithms are designed in the future, shRNA is likely to include further promising application and continue to be a critical component of gene discovery.
Moore
Chris B
CB
Virology, GlaxoSmithKline, Research Triangle Park, NC, USA.
Guthrie
Elizabeth H
EH
Huang
Max Tze-Han
MT
Taxman
Debra J
DJ
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics; D002448:Cell Adhesion; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D055785:Gene Knockdown Techniques / Q000379:methods*; D006801:Humans; D053583:Interleukin-1beta / Q000378:metabolism; D016086:Lentivirus / Q000502:physiology; D034741:RNA, Small Interfering / Q000138:chemical synthesis* / Q000378:metabolism*; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017423:Sequence Analysis, RNA; D014161:Transduction, Genetic; D019065:Virus Assembly
D048868:Adaptor Proteins, Signal Transducing; D053583:Interleukin-1beta; D034741:RNA, Small Interfering
Genes Dev. 2001 Jan 15;15(2):188-200
11157775
Nat Biotechnol. 2004 Mar;22(3):326-30
14758366
Expert Opin Drug Saf. 2002 May;1(1):79-91
12904163
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13110-5
17670939
Genes Dev. 2005 Dec 15;19(24):2979-90
16357216
BMC Biotechnol. 2006 Jan 24;6:7
16433925
J Immunol. 2006 Oct 1;177(7):4252-6
16982856
Nucleic Acids Res. 2004 Feb 09;32(3):936-48
14769950
Nature. 1998 Feb 19;391(6669):806-11
9486653
Nat Biotechnol. 2002 Oct;20(10):1006-10
12244328
Mol Cell. 2002 Aug;10(2):417-26
12191486
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1927-32
14762164
Mol Ther. 2002 Sep;6(3):342-8
12231170
Nat Biotechnol. 2004 Dec;22(12):1573-8
15568018
RNA Biol. 2008 Oct-Dec;5(4):181-8
19182524
Biochem Biophys Res Commun. 2004 Apr 16;316(4):1050-8
15044091
Nature. 2004 Jul 8;430(6996):213-8
15190255
Blood. 2005 Aug 15;106(4):1147-53
15886324
Mol Ther. 2004 Jul;10(1):191-9
15272480
Cell. 2003 Oct 17;115(2):199-208
14567917
Mol Neurodegener. 2008 Nov 01;3:19
18976489
J Immunol. 2009 Feb 15;182(4):2395-404
19201894
Science. 2002 Apr 19;296(5567):550-3
11910072